Press Releases

LONDON --(BUSINESS WIRE)--Nov. 14, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present a general business update during fireside chats at the three following healthcare conferences in New York in

Top-line results compared to baseline at six months: Median apnea-hypopnea index reduction of 66.2% Median oxygen desaturation index reduction of 63.3% LONDON --(BUSINESS WIRE)--Nov. 11, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the

LONDON --(BUSINESS WIRE)--Oct. 30, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. Financial Summary and Highlights (1) Third-quarter revenue of $318.1 million

LONDON --(BUSINESS WIRE)--Oct. 8, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed Susan Podlogar to the Board, effective today. Podlogar will serve on the Compensation and Human Capital Management Committee for the

LONDON --(BUSINESS WIRE)--Sep. 25, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024 at 12 p.m.   London time ( 8 a.m. Eastern Time ).

LONDON --(BUSINESS WIRE)--Aug. 19, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Baird 2024 Global Healthcare Conference in New York .

LONDON --(BUSINESS WIRE)--Jul. 31, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.

LONDON --(BUSINESS WIRE)--Jun. 18, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m.   London time ( 8 a.m. Eastern Time ).

Primary endpoint did not achieve statistical significance in unipolar patient cohort Statistically significant and clinically meaningful benefits seen in select secondary endpoints; no safety concerns identified LONDON --(BUSINESS WIRE)--Jun. 6, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading

LONDON --(BUSINESS WIRE)--May 23, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Goldman Sachs Healthcare Conference in Miami, Florida .

LONDON --(BUSINESS WIRE)--May 1, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.

LONDON --(BUSINESS WIRE)--Apr. 30, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Ahmet Tezel , Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024 . In this newly created position, Tezel will leverage his career

LONDON --(BUSINESS WIRE)--Apr. 25, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc. , is providing notice to U.S. patients regarding a cybersecurity incident that was initially disclosed by the

LONDON --(BUSINESS WIRE)--Mar. 21, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m.   London time ( 8 a.m. Eastern Time ).

LONDON --(BUSINESS WIRE)--Mar. 20, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation , has achieved a positive predictive outcome and will conclude

LONDON --(BUSINESS WIRE)--Mar. 5, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 (the “notes”) to be issued in a private offering only to persons

LONDON --(BUSINESS WIRE)--Mar. 4, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering only to persons reasonably

LONDON --(BUSINESS WIRE)--Mar. 4, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida .

LONDON --(BUSINESS WIRE)--Feb. 21, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024. Financial Summary and Highlights 1 Fourth-quarter revenue of $310.1 million

William Kozy will remain Board Chair LONDON --(BUSINESS WIRE)--Feb. 5, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its Board of Directors named Vladimir A. Makatsaria as the Company’s Chief Executive Officer (CEO) and a member of the Board of

Move Reinforces Focus on Core Cardiopulmonary and Neuromodulation Businesses ACS Standalone Cannulae Products and Accessories to Transition Into Cardiopulmonary Business Unit LONDON --(BUSINESS WIRE)--Jan. 8, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today

LONDON --(BUSINESS WIRE)--Jan. 4, 2024-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2023 results on Wednesday, February 21, 2024 at 1 p.m.   London time ( 8 a.m. Eastern Time ).